SI3204359T1 - Tetrahidroizokinolinski derivati - Google Patents

Tetrahidroizokinolinski derivati

Info

Publication number
SI3204359T1
SI3204359T1 SI201531348T SI201531348T SI3204359T1 SI 3204359 T1 SI3204359 T1 SI 3204359T1 SI 201531348 T SI201531348 T SI 201531348T SI 201531348 T SI201531348 T SI 201531348T SI 3204359 T1 SI3204359 T1 SI 3204359T1
Authority
SI
Slovenia
Prior art keywords
tetrahydroisoquinoline derivatives
tetrahydroisoquinoline
derivatives
Prior art date
Application number
SI201531348T
Other languages
English (en)
Slovenian (sl)
Inventor
Anne Valade
Eric Jnoff
Ali Ates
Pierre Burssens
David Skolc
Zara Sands
Benoit Mathieu
Original Assignee
UCB Biopharma SRL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by UCB Biopharma SRL filed Critical UCB Biopharma SRL
Publication of SI3204359T1 publication Critical patent/SI3204359T1/sl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/472Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D217/00Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/02Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
    • C07D217/06Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines with the ring nitrogen atom acylated by carboxylic or carbonic acids, or with sulfur or nitrogen analogues thereof, e.g. carbamates
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Epidemiology (AREA)
  • Addiction (AREA)
  • Hospice & Palliative Care (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
SI201531348T 2014-10-08 2015-10-06 Tetrahidroizokinolinski derivati SI3204359T1 (sl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP14188174 2014-10-08
PCT/EP2015/073053 WO2016055479A1 (en) 2014-10-08 2015-10-06 Tetrahydroisoquinoline derivatives
EP15775688.3A EP3204359B1 (en) 2014-10-08 2015-10-06 Tetrahydroisoquinoline derivatives

Publications (1)

Publication Number Publication Date
SI3204359T1 true SI3204359T1 (sl) 2020-10-30

Family

ID=51790569

Family Applications (1)

Application Number Title Priority Date Filing Date
SI201531348T SI3204359T1 (sl) 2014-10-08 2015-10-06 Tetrahidroizokinolinski derivati

Country Status (18)

Country Link
US (1) US10105359B2 (cg-RX-API-DMAC10.html)
EP (1) EP3204359B1 (cg-RX-API-DMAC10.html)
JP (1) JP6622299B2 (cg-RX-API-DMAC10.html)
CN (1) CN107001278B (cg-RX-API-DMAC10.html)
BR (1) BR112017007123B1 (cg-RX-API-DMAC10.html)
CA (1) CA2963951C (cg-RX-API-DMAC10.html)
CY (1) CY1123417T1 (cg-RX-API-DMAC10.html)
DK (1) DK3204359T3 (cg-RX-API-DMAC10.html)
EA (1) EA035544B1 (cg-RX-API-DMAC10.html)
ES (1) ES2821821T3 (cg-RX-API-DMAC10.html)
HR (1) HRP20201469T1 (cg-RX-API-DMAC10.html)
HU (1) HUE050664T2 (cg-RX-API-DMAC10.html)
LT (1) LT3204359T (cg-RX-API-DMAC10.html)
PL (1) PL3204359T3 (cg-RX-API-DMAC10.html)
PT (1) PT3204359T (cg-RX-API-DMAC10.html)
RS (1) RS60933B1 (cg-RX-API-DMAC10.html)
SI (1) SI3204359T1 (cg-RX-API-DMAC10.html)
WO (1) WO2016055479A1 (cg-RX-API-DMAC10.html)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108884077A (zh) * 2016-02-25 2018-11-23 阿森纽荣股份公司 糖苷酶抑制剂
CA3018352A1 (en) 2016-04-13 2017-10-19 Ucb Biopharma Sprl Tetrahydroisoquinoline derivatives
CN107698433A (zh) * 2017-09-12 2018-02-16 潍坊滨海石油化工有限公司 苯乙酸的制备方法
DK3717025T3 (da) 2017-12-01 2021-11-22 UCB Biopharma SRL Billeddannende midler
TWI725408B (zh) * 2018-04-20 2021-04-21 美商美國禮來大藥廠 多巴胺d1受體正向異位調節劑
US12358890B2 (en) 2019-07-01 2025-07-15 UCB Biopharma SRL Substituted tetrahydroisoquinoline derivative as a D1 positive allosteric modulator
IL289314B2 (en) * 2019-07-01 2025-09-01 UCB Biopharma SRL Tetrahydroisoquinoline derivative is transformed as a positive allosteric modulator d1
KR20230014706A (ko) * 2020-04-24 2023-01-30 더 리전츠 오브 더 유니버시티 오브 캘리포니아 Nurr1 수용체 조절제 및 이의 용도
CN111943930B (zh) * 2020-08-25 2022-11-01 南京三元阳普医药科技有限公司 Lasmiditan的合成工艺
JP7591138B2 (ja) * 2020-10-07 2024-11-27 イーライ リリー アンド カンパニー ドーパミンd1受容体ポジティブアロステリック調節因子としてのフェニル-3,4-ジヒドロイソキノリン-2(1h)-イル-エタン-1-オン誘導体
EP4267555A1 (en) * 2020-12-03 2023-11-01 UCB Biopharma SRL Octahydroisoquinolinyl derivatives
CN116685308A (zh) * 2020-12-18 2023-09-01 Ucb生物制药有限责任公司 无定形固体分散体
JP7777589B2 (ja) 2020-12-18 2025-11-28 ユーシービー バイオファルマ エスアールエル ジヒドロイソキノリニル誘導体
WO2022129356A1 (en) * 2020-12-18 2022-06-23 UCB Biopharma SRL Prodrugs of 2-(3,5-dichloro-1-methyl-indazol-4-yl)-1-[(1s,3r)-3-(hydroxymethyl)-5-(1-hydroxy-1-methyl-ethyl)-1-methyl-3,4-dihydro-1h-isoquinolin-2-yl]ethanone
LT4263517T (lt) * 2020-12-18 2025-01-10 UCB Biopharma SRL Pakeistasis tetrahidroizochinolino darinys kaip d1 teigiamas alosterinis moduliatorius
JP2024509448A (ja) 2021-03-08 2024-03-01 イーライ リリー アンド カンパニー 幻覚及び認知症に関連する精神病の治療におけるメビダレン及び他のd1陽性アロステリックモジュレーターの使用
BR112023018196A2 (pt) 2021-03-09 2023-12-12 Lilly Co Eli Uso de mevidalen e outros moduladores alostéricos positivos d1 para retardar a progressão da doença de parkinson
CN114671810B (zh) * 2022-03-21 2024-03-22 济南鸿湾生物技术有限公司 一种咪唑苯脲的制备方法
CN115611768B (zh) * 2022-11-14 2024-03-05 郑州大学 一种3,4-二氯苯腈的合成方法
CN118724764B (zh) * 2024-06-07 2025-11-18 绍兴文理学院 一种芳基伯磺酰胺类化合物的制备方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4766131A (en) * 1980-10-17 1988-08-23 Pennwalt Corporation 2-amino (or hydroxy) phenethyl-1,2,3,4-tetrahydroisoquinolines as analgesics
IL162310A0 (en) * 2001-12-19 2005-11-20 Lundbeck & Co As H 3,4-Dihydro-1h-isoquinoloin-2-yl-derivatives
ATE459618T1 (de) * 2004-04-29 2010-03-15 Aventis Pharma Inc 3-piperidinylisochroman-5-ole als dopaminagonisten
EP2125741A1 (en) * 2007-03-01 2009-12-02 Janssen Pharmaceutica, N.V. Tetrahydroisoquinoline compounds as modulators of the histamine h3 receptor

Also Published As

Publication number Publication date
WO2016055479A1 (en) 2016-04-14
BR112017007123A2 (pt) 2017-12-19
PT3204359T (pt) 2020-09-24
EA035544B1 (ru) 2020-07-03
US20170304292A1 (en) 2017-10-26
EP3204359A1 (en) 2017-08-16
CN107001278B (zh) 2020-11-24
CN107001278A (zh) 2017-08-01
PL3204359T3 (pl) 2021-03-22
CY1123417T1 (el) 2021-12-31
CA2963951A1 (en) 2016-04-14
EP3204359B1 (en) 2020-07-01
DK3204359T3 (da) 2020-09-14
LT3204359T (lt) 2020-10-12
RS60933B1 (sr) 2020-11-30
JP6622299B2 (ja) 2019-12-18
US10105359B2 (en) 2018-10-23
JP2017530185A (ja) 2017-10-12
EA201790785A1 (ru) 2017-10-31
HRP20201469T1 (hr) 2020-12-11
HUE050664T2 (hu) 2020-12-28
ES2821821T3 (es) 2021-04-27
CA2963951C (en) 2023-02-28
BR112017007123B1 (pt) 2023-01-31

Similar Documents

Publication Publication Date Title
SI3204359T1 (sl) Tetrahidroizokinolinski derivati
AU361515S (en) Dishrack
AU362944S (en) Lapboard
IL253381B (en) History of h9–pyrrolo–dipyridine
SG11201609205WA (en) Heterocyclyl-butanamide derivatives
PL3418273T3 (pl) Pochodne flawaglin
PL3233890T3 (pl) Pestiwirus
HUE050450T2 (hu) Fluoralkil-fluorén-származékok
IL248773A0 (en) History of naphthyridinedione
IL261055A (en) Derivatives of tetrahydroisoquinoline
IL251005B (en) Pyrido-oxazinone derivatives
AP2016009530A0 (en) Cycloalkyl-linked diheterocycle derivatives
SI3097076T1 (sl) Novi derivati CYP-eikozanoida
PL3119744T3 (pl) Pochodne 2-cyjano-3-cyklopropylo-3-hydroksy-N-arylo-tioakryloamidu
GB2530305B (en) Tracers
GB201707862D0 (en) Tracers
GB201418365D0 (en) Tracers
GB201409664D0 (en) Tracers
AU5584P (en) Laniowa Mandevilla sanderi
AU5583P (en) Lanminnesota Mandevilla sanderi
AU5285P (en) FLOMANRER Mandevilla sanderi
AU5289P (en) FLOMANFOP Mandevilla sanderi
GB201420024D0 (en) Rapiscale
AU2014264V (en) FlatGL Templetonia retusa
GB201407585D0 (en) SMA-Inter Act